



National Securities Market Commission
Markets Directorate General
c/ Edison núm. 4
28006 Madrid

Colmenar Viejo (Madrid), January 18, 2018

Pursuant to article 228 of the consolidated text of the Spanish Securities Market Act, we hereby inform you of the following **SIGNIFICANT EVENT**:

“Pharma Mar, S.A. announces the results of the Phase III clinical trial (CORAIL) with Zepsyre® (lurbinectedin) in platinum-resistant ovarian cancer patients.

The CORAIL trial, comparing Zepsyre® versus topotecan or PLD (liposomal doxorubicin) in platinum resistant ovarian cancer patients has not met the primary end-point of the trial, which was PFS (Progression Free Survival).

The antitumoral activity of the three compounds Zepsyre®, topotecan and PLD, in terms of PFS, has been the same.

In the CORAIL trial Zepsyre® has demonstrated a better safety profile than the control arm.

Results of this trial will be presented at future oncology congresses.”